What are the biggest key takeaways from 2019? In the latest All Access newsletter by Precision for Value we asked our advisors to reflect on the market events for the year by type of payer. Get your complimentary copy here.
Gene therapy has sparked significant interest across the health care industry because it offers the tantalizing possibility of a cure. While gene therapy holds great promise, this field of research is still in its nascent stages, and the optimal methods and solutions for unlocking its full clinical potential are still being defined.
Recent years have brought significant innovation in potentially curative therapies for several diseases. By 2025, the FDA anticipates approving 10 to 20 cell and gene therapy products per year, many of which are intended to be one-time curative treatments.
In the latest edition of IPSOR’s Value in Health, Ross Maclean takes an in depth look at several novel measures of value beyond QALY and how they may apply to European health technology assessment.
Can the tools we use to measure value keep up with the pace at which oncology is advancing? Explore how four different frameworks have evolved over time and the role they play in oncology value assessment.
Read the full article here.
Perhaps we should take a closer look at how Apple devices and other internet of things (IoT) technologies are impacting the healthcare landscape and have the potential to impact the standard of care (SOC) in many disease states in the future.
Read the full article here.
Machine learning is the subset of AI that is related to the development of algorithms that can make accurate predictions of future outcomes via pattern recognition and rules-based logic. Such use of logic and algorithms can improve patient selection, provide predictive long-term outcomes, and reduce the time and cost in the execution of clinical trials.
Read the full article here.
In the latest edition of Journal of Clinical Pathways, Precision experts Chris Dillon, Chrysanthe Peteros and Larry Blandford examine the expanding role of hub support services in the pharmaceutical marketplace, emphasizing their importance as increasingly complex therapies requiring higher degrees of specialization and flexibility are launched.
Is Real-World Evidence to be trusted? Well-documented data can make a difference to both FDA and formulary decision makers, as described by Precision for Value’s Jeremy Schafer, Senior Vice President, Access Experience and Dan Danielson, Senior Director, Access Experience, writing in Managed Healthcare Executive.
To read the full article please click here.
Precision for Value, Senior Vice President, Director of Value Transformation, Maureen Hennessey brings her personal experience to bear in this important Journal of Clinical Pathwaysˆ article on the social determinants of health—exploring where things stand now and opportunities for improvement.
Read the full article here.